Eye Infections
Conditions
Keywords
eyelid warts, candida antigen, eyelid papilloma
Brief summary
intralesional injection of Candida antigens for treating eyelid warts is supposed to have less destructive effect than other surgical interventions
Detailed description
Despite many surgical and interventional modalities of treating ocular warts, all have a destructive nature for this delicate tissue with a high recurrence rate. intralesional injection of Candida antigens was suggested to be an effective and safe treatment for such a condition aim: Providing safe and effective treatment of ocular wart. objective: 1. To determine the efficacy of intralesional injection of Candida antigens in the treatment of eyelids wart 2. To determine the safety of intralesional injection of Candida antigens in the treatment of eyelids wart 3. To report complications of intralesional injection of Candida antigens in the treatment of eyelids wart
Interventions
BIOLOGICALIntralesional injection of Candida albicans 1:20 w/v 10 ml vial (Allergy Laboratories, INC. Oklahoma City, USA.)
Intralesional injection of 0.2 ml of 1/1000 solution of Candida albicans antigen using an insulin syringe directly into the warts; Candida albicans 1:20 w/v 10 ml vial (Allergy Laboratories, INC. Oklahoma City, USA.). The same injection was repeated every 2 weeks until complete clearance for a maximum of six treatment sessions.
Sponsors
Zagazig University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients with cutaneous eyelid viral warts whether single or multiple, with no concurrent systemic or topical treatment for warts. Patients aged more than 12 years, with sensitivity test, showed induration less than or equal to five mm. and patients can understand and comply with the requirements of the trials.
Exclusion criteria
* pregnancy, breastfeeding, patients with immunodeficiency; like diabetics. In addition, patients with a history of hypersensitivity to any used component in this trial, asthma, or allergic skin diseases. Moreover, patients on any treatment modality for warts at least 1 month before the start of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| complete response | after maximum 6 treatment sessions of intralesional injection with 2 weeks between the successive sessions | to report the complete response defined by the efficacy of intralesional injection of Candida antigen in achieving complete disappearance of eyelid warts and return to normal skin |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| partial response | after maximum 6 treatment sessions of intralesional injection with 2 weeks between the successive sessions | to report Partial response which will be considered when wart regress in size by 50%-99%. |
| Failure | after maximum 6 treatment sessions of intralesional injection with 2 weeks between the successive sessions | to report failure which will be considered if less than 50% decrease in wart size. |
| complications | after maximum 6 treatment sessions of intralesional injection with 2 weeks between the successive sessions | to report any complications in the form of hypersensitivity reaction, erythema, or induration |
Countries
Egypt
Outcome results
None listed